End-of-day quote
Shenzhen S.E.
23:00:00 27/06/2024 BST
|
5-day change
|
1st Jan Change
|
8.54
CNY
|
-0.81%
|
|
-3.28%
|
-16.44%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
15,849
|
20,044
|
21,448
|
15,623
|
17,094
|
14,280
|
-
|
-
|
Enterprise Value (EV)
1 |
15,849
|
20,044
|
21,448
|
15,623
|
17,094
|
15,010
|
14,280
|
14,280
|
P/E ratio
|
126
x
|
56.5
x
|
101
x
|
21.8
x
|
20
x
|
14.5
x
|
12.2
x
|
-
|
Yield
|
0.99%
|
1.36%
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.25
x
|
11.8
x
|
-
|
6.7
x
|
5.97
x
|
3.92
x
|
3.37
x
|
-
|
EV / Revenue
|
9.25
x
|
11.8
x
|
-
|
6.7
x
|
5.97
x
|
4.12
x
|
3.37
x
|
-
|
EV / EBITDA
|
68.4
x
|
40.5
x
|
-
|
16.9
x
|
16.8
x
|
11.7
x
|
9.51
x
|
-
|
EV / FCF
|
141
x
|
-
|
-
|
68.5
x
|
22.6
x
|
12.5
x
|
12.1
x
|
7.91
x
|
FCF Yield
|
0.71%
|
-
|
-
|
1.46%
|
4.43%
|
7.99%
|
8.26%
|
12.6%
|
Price to Book
|
6.03
x
|
7.07
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,638,499
|
1,638,466
|
1,638,466
|
1,669,071
|
1,672,639
|
1,672,159
|
-
|
-
|
Reference price
2 |
9.673
|
12.23
|
13.09
|
9.360
|
10.22
|
8.540
|
8.540
|
8.540
|
Announcement Date
|
28/02/20
|
07/04/21
|
30/03/22
|
27/03/23
|
27/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,713
|
1,701
|
-
|
2,331
|
2,866
|
3,645
|
4,237
|
-
|
EBITDA
1 |
231.7
|
494.3
|
-
|
924.8
|
1,020
|
1,283
|
1,501
|
-
|
EBIT
1 |
165.2
|
424
|
-
|
842
|
924
|
1,170
|
1,380
|
1,658
|
Operating Margin
|
9.64%
|
24.92%
|
-
|
36.12%
|
32.24%
|
32.1%
|
32.57%
|
-
|
Earnings before Tax (EBT)
1 |
163.4
|
416.1
|
-
|
833.8
|
919.9
|
1,174
|
1,392
|
1,683
|
Net income
1 |
124.5
|
359
|
206.6
|
703.3
|
847.2
|
990
|
1,174
|
-
|
Net margin
|
7.27%
|
21.1%
|
-
|
30.17%
|
29.56%
|
27.16%
|
27.71%
|
-
|
EPS
2 |
0.0769
|
0.2167
|
0.1300
|
0.4300
|
0.5100
|
0.5900
|
0.7000
|
-
|
Free Cash Flow
1 |
112.4
|
-
|
-
|
228.2
|
757.9
|
1,200
|
1,180
|
1,806
|
FCF margin
|
6.56%
|
-
|
-
|
9.79%
|
26.45%
|
32.92%
|
27.85%
|
-
|
FCF Conversion (EBITDA)
|
48.52%
|
-
|
-
|
24.68%
|
74.33%
|
93.53%
|
78.61%
|
-
|
FCF Conversion (Net income)
|
90.3%
|
-
|
-
|
32.45%
|
89.45%
|
121.21%
|
100.51%
|
-
|
Dividend per Share
|
0.0962
|
0.1667
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/02/20
|
07/04/21
|
30/03/22
|
27/03/23
|
27/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
730
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
0.569
x
|
-
|
-
|
Free Cash Flow
1 |
112
|
-
|
-
|
228
|
758
|
1,200
|
1,180
|
1,806
|
ROE (net income / shareholders' equity)
|
5.2%
|
13.3%
|
-
|
23.8%
|
24.9%
|
37%
|
56.2%
|
-
|
ROA (Net income/ Total Assets)
|
4.33%
|
10.7%
|
-
|
16.5%
|
18.4%
|
26.8%
|
35.6%
|
-
|
Assets
1 |
2,876
|
3,365
|
-
|
4,255
|
4,604
|
3,694
|
3,298
|
-
|
Book Value Per Share
|
1.600
|
1.730
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
0.1800
|
0.2800
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
183
|
138
|
-
|
471
|
195
|
166
|
444
|
120
|
Capex / Sales
|
10.7%
|
8.12%
|
-
|
20.2%
|
6.81%
|
4.55%
|
10.48%
|
-
|
Announcement Date
|
28/02/20
|
07/04/21
|
30/03/22
|
27/03/23
|
27/03/24
|
-
|
-
|
-
|
Last Close Price
8.54
CNY Average target price
19.54
CNY Spread / Average Target +128.81% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.44% | 1.97B | | +1.94% | 95.18B | | -4.34% | 37.55B | | +75.79% | 28.2B | | -14.61% | 15.63B | | -3.46% | 13.63B | | -12.31% | 11.5B | | +184.77% | 10.81B | | -54.13% | 9.23B | | +6.22% | 9.09B |
Biopharmaceuticals
|